Navigation Links
FDA Warns Consumers about Counterfeit Alli
Date:1/18/2010

The counterfeit products contain controlled substance sibutramine

SILVER SPRING, Md., Jan. 18 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration is today warning consumers about a counterfeit and potentially harmful version of Alli 60 mg capsules (120 count refill kit).

(Logo: http://www.newscom.com/cgi-bin/prnh/20090824/FDALOGO)

Preliminary laboratory tests conducted by GlaxoSmithKline (GSK) -- the maker of the FDA-approved over-the-counter weight-loss product -- revealed that the counterfeit version did not contain orlistat, the active ingredient in its product. Instead, the counterfeit product contained the controlled substance sibutramine. Sibutramine is a drug that should not be used in certain patient populations or without physician oversight.  Sibutramine can also interact in a harmful way with other medications the consumer may be taking.

Consumers began reporting suspected counterfeit Alli to GSK in early December 2009.  GSK has determined that the counterfeit product has been sold over the internet. However, there is no evidence at this time that the counterfeit Alli product has been sold through other channels, such as retail stores.

The counterfeit Alli product looks similar to the authentic product, with a few notable differences. The counterfeit Alli has:

  • Outer cardboard packaging missing a "Lot" code;
  • Expiration date that includes the month, day, and year (e.g., 06162010); authentic Alli expiration date includes only the month and year (e.g.,: 05/12);
  • Packaging in a plastic bottle that has a slightly taller and wider cap with coarser ribbing than the genuine product;
  • Plain foil inner safety seal under the plastic cap without any printed words; the authentic product seal is printed with "SEALED for YOUR PROTECTION";
  • Contains larger capsules with a white powder, instead of small white pellets.

Consumers who believe they have received counterfeit Alli are asked to contact the FDA's Office of Criminal Investigations (OCI) by calling 800-551-3989 or by visiting the OCI Web site (http://www.fda.gov/OCI).

Health care professionals and consumers are encouraged to report adverse events that may be related to the use of these counterfeit products to the FDA's MedWatch Program by phone at 1-800-FDA-1088, by fax at 1-800-FDA-0178, or by mail at: MedWatch, HF-2, FDA, 5600 Fishers Lane, Rockville, MD 20852-9787.

Pictures of counterfeit Alli samples provided by GSK can be viewed at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm197857.htm

Media Inquiries: Tom Gasparoli, 301-796-4737, thomas.gasparoli@fda.hhs.gov

Consumer Inquiries: 888-INFO-FDA

SOURCE U.S. Food and Drug Administration

RELATED LINKS
http://www.fda.gov/

'/>"/>

SOURCE U.S. Food and Drug Administration
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Toxic Chemical bisphenol A Still Not Banned By FDA; Schumer, Gillibrand Call for Ban; Govt Official Warns Public
2. Orkin Warns of Four Pests to Avoid this Fourth of July
3. New Federal Stem Cell Rules Would Hinder Existing Research, Consumer Group Warns
4. Agriculture Department Warns Consumers of Tainted Raw Milk Sold by Lebanon County Dairy
5. Agriculture Department Warns Consumers of Tainted Raw Milk Sold by Chester County Dairy
6. Survey Finds At-Risk Consumers Interested in OTC Statin
7. Dog Law Officers Crackdown on Unsatisfactory Kennels Protecting Animals, Consumers
8. Lilly Releases Latest Value of Medicine Resource Guide About Key Issues Facing the Pharmaceutical Industry
9. DynaVox EyeMax Featured in Good Morning America Segment About Man Thought To Be in Coma for 23 Years
10. New Web Sites Educate About Triglycerides and HDL Cholesterol
11. Actress Debi Mazar Talks About her Familys Experience with Bipolar Depression
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... March 23, 2017  The goal of the ... identify and track prescription drugs as they are distributed ... response to requirements from US FDA to better protect ... dangerous medicines. Blockchain startup Chronicled, which ... chips and blockchain technology and recently raised $6.25M, and ...
(Date:3/23/2017)... Prima BioMed has presented encouraging ... IMP321 in combination with Keytruda, with one of the ... a complete response. Recruitment in the second cohort is ... fully recruited by Q317. Preliminary efficacy data from the ... are expected mid-year (recruitment in the 226-patient Phase IIb ...
(Date:3/23/2017)... , March 23, 2017 ... ended the trading session at 5,821.64, up 0.48%; ... to finish at 20,661.30; and the S&P 500 ... broad based as six out of nine sectors ... has initiated reports coverage on the following Medical ...
Breaking Medicine Technology:
(Date:3/23/2017)... ... ... feature 150+ Hospital and Health System Executive Speakers including: , , ... of the United States of America: George W. Bush , Boxing Legend, Successful ... Ray Leonard , JD, Chairperson, McGuireWoods LLP: Amber McGraw Walsh , ...
(Date:3/23/2017)... ... March 23, 2017 , ... ... help improve all aspects of people’s health and nutrition, announced its product Leyzene ... , Natural Subsistence develops nutritional supplements that help people improve all aspects ...
(Date:3/23/2017)... ... 2017 , ... The American Board of Quality Assurance and Utilization Review Physicians ... to Health Care Quality and Management and Patient Safety. , It is with appreciation ... but also to the Health Care Quality and Patient Safety movements. Diplomates and Members ...
(Date:3/23/2017)... ... March 23, 2017 , ... ... the New MEDDEV 2.7/1 Rev. 4 Guidance, **An FDAnews Webinar**, April 4, ... How will the new EU MDR language change the way manufacturers approach ...
(Date:3/23/2017)... (PRWEB) , ... March 23, 2017 , ... “Beyond and ... “Beyond and Back” is the creation of published author Bonetta Rose, a wife, mother ... our lives. , Published by Christian Faith Publishing, Bonetta Rose‘s new book presents actual ...
Breaking Medicine News(10 mins):